KCNQ2 Gene Changes Linked To Different Baby Seizure Outcomes

What was studied

This study looked at 30 newborns with epilepsy associated with changes in the KCNQ2 gene. The children were seen at 2 centers between 2019 and 2024. All underwent whole-exome sequencing with Sanger confirmation.

The researchers reviewed when seizures started, what the seizures looked like, EEG and MRI findings, which gene variants were present, treatment responses, and neurodevelopmental outcomes at follow-up. They grouped children into 2 epilepsy patterns using International League Against Epilepsy criteria: self-limited (familial) neonatal epilepsy and developmental and epileptic encephalopathy (DEE).

What they found

Most babies had seizures in the first week of life, with a median age of 3 days, and focal tonic seizures were typical. EEG was abnormal in 90% of patients. Very severe early EEG patterns, such as burst-suppression or profound discontinuity, were consistently associated with adverse neurodevelopmental outcomes. MRI was often normal or showed only nonspecific changes.

At follow-up, 63% were classified as self-limited (familial) neonatal epilepsy and 37% as DEE. Seizure freedom by the last follow-up was 93%. Normal development was reported in 63%, and developmental delays were seen only in the DEE group.

The type and location of the KCNQ2 variant appeared to matter. Missense variants in transmembrane parts of the gene, especially the S5-pore-S6 region, were enriched in DEE. Variants in the C-terminal or other nontransmembrane regions were associated with the self-limited form and more favorable outcomes. All 5 single-allele truncating or NMD-type variants in this study were classified in the self-limited group. Oxcarbazepine was often associated with seizure control after phenobarbital nonresponse, but the study cannot show that oxcarbazepine caused the improvement.

Limits of the evidence

This was a retrospective study, so the researchers looked back at existing records rather than testing treatments in a planned trial. It included 30 patients from 2 centers, which is a relatively small sample. Because treatment was not assigned randomly, the study cannot show that one medicine worked better than another. Some genetic findings were also uncertain: 2 children had 2 heterozygous variants, but the researchers did not know whether those variants were on the same or different copies of the gene, and 1 recurrent variant was considered likely benign, limiting conclusions about 2 pathogenic alleles.

For families and caregivers

For families, this study suggests that KCNQ2-related neonatal epilepsy can follow different paths. Many babies in this group became seizure-free, and many had normal development, especially those classified with the self-limited form. Early EEG findings and the location of the KCNQ2 variant may help doctors estimate risk and plan follow-up.

The study also supports close developmental monitoring, especially for children with DEE, severe early EEG patterns, or variants in transmembrane or pore regions. The treatment finding about oxcarbazepine is only an association, so families should not assume it is proven to be the best option based on this study alone.

What to watch next

Larger prospective studies, including phenotype-stratified studies, are needed to better assess outcomes by variant type and treatment associations.

Terms in this summary

KCNQ2

A gene that helps control electrical activity in brain cells.

EEG

A test that records the brain's electrical activity.

MRI

A scan that makes detailed pictures of the brain.

DEE

Developmental and epileptic encephalopathy, a severe epilepsy condition linked with developmental problems.

missense variant

A gene change that swaps one building block of a protein for another.

transmembrane region

The part of a protein that sits in the cell membrane.

burst-suppression

A very abnormal EEG pattern with bursts of activity separated by quiet periods.

observational study

A study that looks at what happened in usual care, without randomly assigning treatments.